CARLSBAD, Calif.--(BUSINESS WIRE)--Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKN); (OTCBB:INKND), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that its proprietary NanoShrink™ material has shown to produce superior microfluidic and point-of-care test prototypes in a landmark study conducted by the University of California Irvine’s (UCI) Department of Biomedical Engineering. The UCI findings were published in the article, “Better Shrinkage than Shrinky-Dinks” online on March 24, 2010 in a leading academic journal, “Lab on a Chip,” a Royal Society of Chemistry Journal. To read the article, please visit the Company’s website at www.shrinknano.com.
